164 related articles for article (PubMed ID: 28404378)
1. Axl molecular targeting counteracts aggressiveness but not platinum-resistance of ovarian carcinoma cells.
Corno C; Gatti L; Arrighetti N; Carenini N; Zaffaroni N; Lanzi C; Perego P
Biochem Pharmacol; 2017 Jul; 136():40-50. PubMed ID: 28404378
[TBL] [Abstract][Full Text] [Related]
2. AXL Downstream Targeting Unravels Synergistic Drug Combinations in Ovarian Carcinoma Cells.
Alampi DM; Ciusani E; Carenini N; Corna E; Gatti L; Corno C
Anticancer Res; 2019 Jul; 39(7):3803-3808. PubMed ID: 31262907
[TBL] [Abstract][Full Text] [Related]
3. Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells.
Kim NY; Lee HY; Lee C
Int J Oncol; 2015 Jul; 47(1):353-60. PubMed ID: 25975389
[TBL] [Abstract][Full Text] [Related]
4. Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol.
Perego P; Romanelli S; Carenini N; Magnani I; Leone R; Bonetti A; Paolicchi A; Zunino F
Ann Oncol; 1998 Apr; 9(4):423-30. PubMed ID: 9636834
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells.
Suh YA; Jo SY; Lee HY; Lee C
Int J Oncol; 2015 Mar; 46(3):1405-11. PubMed ID: 25544427
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis.
Tian M; Chen XS; Li LY; Wu HZ; Zeng D; Wang XL; Zhang Y; Xiao SS; Cheng Y
Acta Pharmacol Sin; 2021 Jul; 42(7):1180-1189. PubMed ID: 33149145
[TBL] [Abstract][Full Text] [Related]
7. Caffeic acid phenethyl ester targets ubiquitin-specific protease 8 and synergizes with cisplatin in endometrioid ovarian carcinoma cells.
Colombo D; Gatti L; Sjöstrand L; Carenini N; Costantino M; Corna E; Arrighetti N; Zuccolo M; De Cesare M; Linder S; D'Arcy P; Perego P
Biochem Pharmacol; 2022 Mar; 197():114900. PubMed ID: 34995485
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.
Quinn JM; Greenwade MM; Palisoul ML; Opara G; Massad K; Guo L; Zhao P; Beck-Noia H; Hagemann IS; Hagemann AR; McCourt CK; Thaker PH; Powell MA; Mutch DG; Fuh KC
Mol Cancer Ther; 2019 Feb; 18(2):389-398. PubMed ID: 30478151
[TBL] [Abstract][Full Text] [Related]
9. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
10. Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds.
Benedetti V; Perego P; Luca Beretta G; Corna E; Tinelli S; Righetti SC; Leone R; Apostoli P; Lanzi C; Zunino F
Mol Cancer Ther; 2008 Mar; 7(3):679-87. PubMed ID: 18347153
[TBL] [Abstract][Full Text] [Related]
11. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.
Corno C; Stucchi S; De Cesare M; Carenini N; Stamatakos S; Ciusani E; Minoli L; Scanziani E; Argueta C; Landesman Y; Zaffaroni N; Gatti L; Perego P
Biochem Pharmacol; 2018 Jan; 147():93-103. PubMed ID: 29155058
[TBL] [Abstract][Full Text] [Related]
12. PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells.
Arrighetti N; Cossa G; De Cecco L; Stucchi S; Carenini N; Corna E; Gandellini P; Zaffaroni N; Perego P; Gatti L
Toxicol Appl Pharmacol; 2016 Nov; 310():9-19. PubMed ID: 27554045
[TBL] [Abstract][Full Text] [Related]
13. Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.
Bansal N; Mishra PJ; Stein M; DiPaola RS; Bertino JR
Oncotarget; 2015 Jun; 6(17):15321-31. PubMed ID: 26036314
[TBL] [Abstract][Full Text] [Related]
14. Mistletoe (Viscum album) extract targets Axl to suppress cell proliferation and overcome cisplatin- and erlotinib-resistance in non-small cell lung cancer cells.
Kim S; Kim KC; Lee C
Phytomedicine; 2017 Dec; 36():183-193. PubMed ID: 29157814
[TBL] [Abstract][Full Text] [Related]
15. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
[TBL] [Abstract][Full Text] [Related]
16. Curcumin-induced downregulation of Axl receptor tyrosine kinase inhibits cell proliferation and circumvents chemoresistance in non-small lung cancer cells.
Kim KC; Baek SH; Lee C
Int J Oncol; 2015 Dec; 47(6):2296-303. PubMed ID: 26498137
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
18. Anticancer effect of luteolin is mediated by downregulation of TAM receptor tyrosine kinases, but not interleukin-8, in non-small cell lung cancer cells.
Lee YJ; Lim T; Han MS; Lee SH; Baek SH; Nan HY; Lee C
Oncol Rep; 2017 Feb; 37(2):1219-1226. PubMed ID: 28035396
[TBL] [Abstract][Full Text] [Related]
19. Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma.
Pinato DJ; Brown MW; Trousil S; Aboagye EO; Beaumont J; Zhang H; Coley HM; Mauri FA; Sharma R
Br J Cancer; 2019 Mar; 120(5):512-521. PubMed ID: 30765873
[TBL] [Abstract][Full Text] [Related]
20. YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC.
Ghiso E; Migliore C; Ciciriello V; Morando E; Petrelli A; Corso S; De Luca E; Gatti G; Volante M; Giordano S
Neoplasia; 2017 Dec; 19(12):1012-1021. PubMed ID: 29136529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]